StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd.

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)

Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –

BeOne Medicines GAAP Diluted Earnings (Loss) per ADS by Year

GAAP Diluted Earnings (Loss) per ADS ($/ADS, 1 ADS = 13 Ordinary Shares) ($)

QuarterlyAnnual

BeOne Medicines GAAP Diluted Earnings (Loss) per ADS: $2.53 in FY2025, down 141.3% from a year earlier.

Latest, FY2025
2.53
Period ended Dec 31, 2025
Change on a year earlier
-141.3%
-6.12 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-26) ↗

Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Form 8-K Non-GAAP Reconciliations.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGAAP Diluted Earnings (Loss) per ADS ($/ADS, 1 ADS = 13 Ordinary Shares) ($)Year on yearSource
FY2025Dec 31, 20252.53-141.3%Form 10-K (filed 2026-02-26) ↗
FY2024Dec 31, 2024-6.12-27.6%Form 10-K (filed 2026-02-26) ↗
FY2023Dec 31, 2023-8.45-56.5%Form 10-K (filed 2026-02-26) ↗
FY2022Dec 31, 2022-19.43+23.7%Form 10-K (filed 2025-02-27) ↗
FY2021Dec 31, 2021-15.71-19.3%Form 10-K (filed 2024-02-26) ↗
FY2020Dec 31, 2020-19.47+23.2%Form 10-K (filed 2023-02-27) ↗
FY2019Dec 31, 2019-15.80–Form 10-K (filed 2022-02-28) ↗

Breakdown

What makes up GAAP Diluted Earnings (Loss) per ADS

Cite this data

StockData. (2026). BeOne Medicines GAAP Diluted Earnings (Loss) per ADS ($), annual FY2019–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/eps-ads-diluted

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.